Biocon рдХреЗ CMD Shreehas Tambe рд╕реЗ рдЦрд╛рд╕ рдмрд╛рддрдЪреАрдд, рдХрдВрдкрдиреА рдХрд╛ рдЖрдЧреЗ рдХреНрдпрд╛ рдкреНрд▓рд╛рди? | Biocon Q2 Results
CNBC Awaaz. ┬╖ 05 Nov 2026 ┬╖ 5 min
Management interview of Biocon Ltd (BIOCON), with 7 key numbers discussed.
- Shreehas Tambe, MD & CEO, Biocon
Biocon reported that H1FY25 tracked its planned trajectory, with the biopharma business expanding 11% YoY to Rs 7,200 cr and consolidated net profit jumping 57%. Management explained that Q2 reported growth and biosimilar margins faced a slight optical impact because shipments worth about 5% of revenue crossed from September to October, which will be recognized in Q3. Generics showed strong turnaround with an 800 bps EBITDA margin improvement to +7%. Management stated business performance will improve in the second half of the year.